Internet Promotion Warning Letters Continue In Guidance Vacuum
This article was originally published in The Gray Sheet
Executive Summary
Counsel for OmniCorder Technologies is preparing a response to an April 18 warning letter citing Internet promotions representing the firm's BioScan system "as a stand-alone diagnostic device for breast cancer detection," the company says.
You may also be interested in...
Website Off-Label Reprints May Require Physician-Only Access, FDAer Says
Device companies disseminating peer-reviewed journal articles discussing off-label uses to health care practitioners over the Internet may need to develop security mechanisms to ensure that only those individuals could access the information, FDA says.
Website Off-Label Reprints May Require Physician-Only Access, FDAer Says
Device companies disseminating peer-reviewed journal articles discussing off-label uses to health care practitioners over the Internet may need to develop security mechanisms to ensure that only those individuals could access the information, FDA says.
Interpore Cross Cited For BonePlast Journal Ad In FDA Warning Letter
Interpore Cross may face FDA misbranding and adulteration actions if the company provides reprints of journal articles detailing use of the firm's BonePlast bone void filler with antibiotics, growth factors or other therapeutics.